BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15898975)

  • 1. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years.
    Rienzo VD; Minelli M; Musarra A; Sambugaro R; Pecora S; Canonica WG; Passalacqua G
    Clin Exp Allergy; 2005 May; 35(5):560-4. PubMed ID: 15898975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of sublingual immunotherapy with one or multiple pollen allergens in children.
    Agostinis F; Foglia C; Landi M; Cottini M; Lombardi C; Canonica GW; Passalacqua G
    Allergy; 2008 Dec; 63(12):1637-9. PubMed ID: 19032238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled, trial.
    La Grutta S; Arena A; D'Anneo WR; Gammeri E; Leonardi S; Trimarchi A; Platania D; La Rosa M
    Eur Ann Allergy Clin Immunol; 2007 Feb; 39(2):40-4. PubMed ID: 17441414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
    Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years.
    Fiocchi A; Pajno G; La Grutta S; Pezzuto F; Incorvaia C; Sensi L; Marcucci F; Frati F
    Ann Allergy Asthma Immunol; 2005 Sep; 95(3):254-8. PubMed ID: 16200816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sublingual immunotherapy in the treatment of children.
    Pham-Thi N; de Blic J; Scheinmann P
    Allergy; 2006; 61 Suppl 81():7-10. PubMed ID: 16792599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year).
    Passalacqua G; Musarra A; Pecora S; Amoroso S; Antonicelli L; Cadario G; Di Gioacchino M; Lombardi C; Ridolo E; Sacerdoti G; Schiavino D; Senna G
    Pediatr Allergy Immunol; 2007 Feb; 18(1):58-62. PubMed ID: 17295800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase.
    Giordano T; Quarta C; Bruno ME; Falagiani P; Riva G
    Eur Ann Allergy Clin Immunol; 2006 Nov; 38(9):310-2. PubMed ID: 17191751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Multicenter drug surveillance of sublingual immunotherapy in allergic patients].
    Almagro E; Asensio O; Bartolomé JM; Bosque M; de la Hoz B; Dolz I; Elorza J; Ferreiro M; García JM; Losada E
    Allergol Immunopathol (Madr); 1995; 23(4):153-9. PubMed ID: 8553989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age and indications to SLIT.
    Terracciano L; Calcinai E; Avitabile S; Galli E
    Int J Immunopathol Pharmacol; 2009; 22(4 Suppl):5-8. PubMed ID: 19944002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study.
    Lombardi C; Gargioni S; Melchiorre A; Tiri A; Falagiani P; Canonica GW; Passalacqua G
    Allergy; 2001 Oct; 56(10):989-92. PubMed ID: 11576079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites.
    Passalacqua G; Pasquali M; Ariano R; Lombardi C; Giardini A; Baiardini I; Majani G; Falagiani P; Bruno M; Canonica GW
    Allergy; 2006 Jul; 61(7):849-54. PubMed ID: 16792583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of sublingual-swallow immunotherapy: an analysis of published studies.
    Gidaro GB; Marcucci F; Sensi L; Incorvaia C; Frati F; Ciprandi G
    Clin Exp Allergy; 2005 May; 35(5):565-71. PubMed ID: 15898976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
    Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
    Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sublingual immunotherapy in polysensitized allergic patients with rhinitis and/or asthma: allergist choices and treatment efficacy.
    Ciprandi G; Cadario G; Di Gioacchino M; Gangemi S; Minelli M; Ridolo E; Valle C; Verini M; Boccardo R; Incorvaia C; Puccinelli P; Scurati S; Frati F
    J Biol Regul Homeost Agents; 2009; 23(3):165-71. PubMed ID: 19828093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy.
    Schiappoli M; Ridolo E; Senna G; Alesina R; Antonicelli L; Asero R; Costantino MT; Longo R; Musarra A; Nettis E; Crivellaro M; Savi E; Massolo A; Passalacqua G
    Clin Exp Allergy; 2009 Oct; 39(10):1569-74. PubMed ID: 19486027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of sublingual specific immunotherapy in patients with respiratory allergy to Alternaria alternata: a randomised, assessor-blinded, patient-reported outcome, controlled 3-year trial.
    Pozzan M; Milani M
    Curr Med Res Opin; 2010 Dec; 26(12):2801-6. PubMed ID: 21050060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model for management of sublingual immunotherapy.
    Frati F; Sensi L; Di Rienzo V; Senna GE; Incorvaia C; Marcucci F
    Eur Ann Allergy Clin Immunol; 2003 Feb; 35(2):56-60. PubMed ID: 12674040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study.
    Pajno GB; Caminiti L; Vita D; Barberio G; Salzano G; Lombardo F; Canonica GW; Passalacqua G
    J Allergy Clin Immunol; 2007 Jul; 120(1):164-70. PubMed ID: 17543376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens.
    Pfaar O; Klimek L; Fischer I; Sieber J; Amoroso S; Moreno Aguilar C; Shah K; Mösges R
    Int Arch Allergy Immunol; 2009; 150(1):102-8. PubMed ID: 19339808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.